XML 17 R6.htm IDEA: XBRL DOCUMENT v3.20.2
STATEMENTS OF CASH FLOWS - USD ($)
3 Months Ended 6 Months Ended
Aug. 31, 2020
May 31, 2020
Aug. 31, 2019
May 31, 2019
Aug. 31, 2020
Aug. 31, 2019
CASH FLOWS FROM OPERATING ACTIVITIES            
Net loss $ (328,540) $ (457,970) $ (410,220) $ (468,314) $ (786,510) $ (878,534)
Adjustments to reconcile net loss to net cash used in operating activities:            
FDA clinical trial expenses paid directly by S.R. Burzynski, M.D., Ph.D.         515,377 600,434
Changes in operating assets and liabilities            
Prepaids         18,439 (23,521)
Accounts payable         25,335 (8,148)
Accrued liabilities         6,573 27,885
NET CASH USED IN OPERATING ACTIVITIES         (220,786) (281,884)
CASH FLOWS FROM FINANCING ACTIVITIES            
Contribution of capital         222,334 282,284
NET CASH PROVIDED BY FINANCING ACTIVITIES         222,334 282,284
NET INCREASE IN CASH         1,548 400
CASH AT BEGINNING OF PERIOD   $ 163   $ 708 163 708
CASH AT END OF PERIOD $ 1,711   $ 1,108   $ 1,711 $ 1,108